Golden
Rubius Therapeutics

Rubius Therapeutics

Rubius Therapeutics is a biotechnology company using stem cells to develop red blood cell cellular therapies.

Rubius Therapeutics is a biotechnology company using stem cells to develop red blood cell cellular therapies that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Avak Kahvejian.

Funding

Series A

On December 9, 2015 Rubius Therapeutics announced completing their series A funding round with $25 million in funding from Flagship Pioneering. 

Series B

On June 21, 2017 Rubius Therapeutics completed their series B funding round with $120 million in funding from Flagship Pioneering. 

Series C

On March 1, 2018 Rubius Therapeutics closed their series C funding round with $100 million in funding from Flagship Pioneering and 26 other participating investors. 



Timeline

March 1, 2018

Series C funding round

On March 1, 2018 Rubius Therapeutics closed their series C funding round with $100 million in funding from Flagship Pioneering and 26 other participating investors. 

June 21, 2017

Series B funding round

On June 21, 2017 Rubius Therapeutics completed their series B funding round with $120 million in funding from Flagship Pioneering. 

December 12, 2015

Series A funding round

On December 9, 2015 Rubius Therapeutics announced completing their series A funding round with $25 million in funding from Flagship Pioneering. 

People

Name
Role
Related Golden topics







Further reading

Title
Author
Link
Type
Date

Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria

Rubius Therapeutics

Web



Documentaries, videos and podcasts

Title
Date
Link

Rubius Therapeutics

October 23, 2017

Rubius Therapeutics: Pioneering a New Era of Cellular Therapies

November 15, 2015

Companies

Company
CEO
Location
Products/Services









References